Indeed, non-cirrhotic patients with normal ALT levels are generally advised not to start antiviral therapy irrespective of relatively high values of HBV DNA, unless they are thought to have significant liver disease assessed through liver histopathology or unless they have a family history of cirrhosis or HCC. This evidence concerns the gene GPT and Cirrhosis.